Welcome to our dedicated page for MediWound Ltd. SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MediWound Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MediWound Ltd.'s regulatory disclosures and financial reporting.
MediWound Ltd. submitted a Form 6-K reporting corporate disclosures and attachments. The filing lists the company's principal executive office address in Yavne, Israel, and indicates the company files annual reports on Form 20-F. The exhibits include a legal opinion from Meitar | Law Offices and Exhibit 10.1, a Form of Securities Purchase Agreement dated September 29, 2025, executed by the company and the purchasers listed on the signature pages. The filing also includes the consent of Meitar as Exhibit 23.1. No financial tables or earnings data are provided in the disclosed text.
MediWound Ltd. is offering 1,734,105 ordinary shares (MDWD) in a registered placement to institutional and accredited investors. The prospectus supplement states the company’s shares trade on Nasdaq and the last reported price was $17.89 on September 26, 2025, while the offering price described is $17.30 per share. Net proceeds are estimated at approximately $27.4 million after fees, which MediWound intends to use primarily to support the pre-commercial activities for EscharEx, expand large-scale manufacturing capacity and for general corporate purposes. The filing discloses immediate dilution to new investors: net tangible book value was $1.84 per share as of June 30, 2025, rising to an as-adjusted $3.76 per share after the offering, producing approximately $13.54 per-share dilution for purchasers. The placement agent is H.C. Wainwright & Co., with a cash fee of 7.0% of gross proceeds (subject to reductions for certain investors) and additional expense allowances. The supplement also summarizes pipeline and corporate facts: NexoBrid is approved in more than 40 countries, EscharEx is in a global Phase III VALUE trial enrolling 216 VLU patients across ~40 U.S. and European sites with an interim sample-size assessment planned mid-2026, and MW005 has positive Phase I/II data. The document highlights fundraising, dilution, tax and legal disclosures and incorporates by reference the company’s Form 20-F and other filings.
MediWound Ltd. announced a $30 million registered direct offering of ordinary shares. The disclosure in this Form 6-K references a press release titled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares." The filing provides the existence and size of the offering but does not include pricing, number of shares, underwriters, or stated use of proceeds within the text provided. Additional offering particulars and material terms are not present in the supplied content.
HOLD Alapkezelo Zrt. filed a Schedule 13G reporting beneficial ownership of 703,429 common shares of MediWound Ltd., representing approximately 6.52% of the outstanding common stock based on 10,793,057 shares outstanding as of December 31, 2024. The filer is a Hungarian investment fund management company (not SEC-registered) with sole voting and dispositive power over the reported shares. The filing states the shares were not acquired to influence control of the issuer. MediWound's principal executive offices are listed in Yavne, Israel.
MediWound Ltd. reports that its Chairman, Nachum (Homi) Shamir, and Chief Executive Officer, Ofer Gonen, each individually purchased the company’s ordinary shares in open market transactions on August 18, 2025. These insider purchases totaled 11,200 ordinary shares at an average price of $17.74 per share.
The company states that all trades complied with its insider trading policy. This report is also being used to incorporate its contents by reference into multiple existing MediWound registration statements on Forms S-8 and F-3 filed with the SEC.
MediWound Ltd. filed a Form 6-K reporting submission of its quarterly materials for the period ended June 30, 2025. The report attaches a press release and the companys financial statements for the quarter and six months ended June 30, 2025, formatted in XBRL. The filing lists the specific XBRL sub-exhibits and states these materials are incorporated by reference into multiple S-8 and F-3 registration statements. The document does not include numerical results or management commentary within the main text of the 6-K itself.
Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 570,326 MediWound common shares, representing 5.2% of outstanding shares based on 10,793,057 shares. The position comprises 407,061 issued common shares and 163,265 shares issuable upon exercise of warrants. Each reporting person discloses shared voting and dispositive power over 407,061 shares and no sole voting or dispositive power. The reported warrants contain a blocker provision preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%. The advisor and Mr. Salamon disclaim beneficial ownership of shares held by the fund.